Novo Nordisk A/S is to acquire Dicerna Pharmaceuticals Inc, a company developing candidate RNA interference (RNAi) therapeutics for multiple diseases including cardiometabolic, viral, and chronic liver indications. Under the terms of the agreement, Novo will acquire all of the outstanding shares of Dicerna for $38.25 per share for a total equity value of $3.3 billion.
